0001237899-19-000031.txt : 20191213 0001237899-19-000031.hdr.sgml : 20191213 20191213160539 ACCESSION NUMBER: 0001237899-19-000031 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191211 FILED AS OF DATE: 20191213 DATE AS OF CHANGE: 20191213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHLEIFER LEONARD S CENTRAL INDEX KEY: 0001218629 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 191284649 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2019-12-11 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001218629 SCHLEIFER LEONARD S 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 1 0 0 President & CEO Common Stock 2019-12-12 4 M 0 124900 21.25 A 448962 D Common Stock 2019-12-12 4 F 0 64754 377.16 D 384208 D Common Stock 2019-12-12 4 M 0 187500 21.25 A 571708 D Common Stock 2019-12-12 4 F 0 97209 377.16 D 474499 D Common Stock 5816 I By 401(k) Plan Common Stock 100000 I by 2019 GRAT Non-Qualified Stock Option (right to buy) 21.25 2019-12-12 4 M 0 124900 0.0 D 2019-12-18 Common Stock 124900 187500 D Non-Qualified Stock Option (right to buy) 21.25 2019-12-12 4 M 0 187500 0.0 D 2019-12-18 Common Stock 187500 0 D Non-Qualified Stock Option (right to buy) 372.46 2019-12-11 4 A 0 81278 0.0 A 2029-12-11 Common Stock 81278 81278 D Performance Stock Units 2019-12-11 4 A 0 25155 0.0 A Common Stock 25155 25155 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). The stock option award vests in four equal annual installments, commencing one year after the date of grant. The option became exercisable with respect to all shares underlying the option on December 31, 2012, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2012. Each performance-based restricted stock unit ("PSU") represents the contingent right to receive one share of the issuer's common stock at vesting. The amount reported reflects the maximum number of PSUs that may vest based upon the achievement of certain performance metrics related to total shareholder return over four-year and/or five-year performance periods ending on December 11, 2023 and December 11, 2024, respectively. Between 50% and 225% of the target number of PSUs (i.e., between 50% and 225% of 11,180 PSUs) may vest upon achievement of predetermined total shareholder return percentages derived from compound annual growth rates of 5% to 15% for the applicable performance period. If none of the performance metrics are achieved at the conclusion of the performance periods, the award expires. /s/**Leonard S. Schleifer 2019-12-13